There is considerable excitement about the potential for simulation and digital twin technology to drive the personalised health agenda through better diagnosis of disease, faster and cheaper clinical trials and better training and engagement with physicians. Overcoming the considerable technical, ethical and regulatory challenges will not, however, be easy, and so how can pharma benefit now and how should it prepare for the future?
To help you sift market potential from scientific ambition we interviewed, in The Future of Personalised Medicine: The Role of Simulation and Digital Twins, knowledgeable experts to give you a clear perspective of what is reality now and future development pathways this rapidly emerging field could take.
Experts explore simulation and digital twin technology
- Which disease areas will specifically benefit from simulation and digital twins in terms of diagnosis?
- How can pharma leverage the diagnostic opportunities offered by simulation and digital twins?
- How will simulation and digital twins of human body functions lead to more accurate and efficient clinical development?
- How will simulation and digital twins influence the personalisation of treatments?
- What patient data and medical records will be of value to pharma in developing simulations and digital twins and what are the data security and privacy implications of accessing such data?
- How can pharma work with technology and software companies to develop effective simulation and digital twin solutions?
